Morken CeCelia 4

What Happened

• Morken CeCelia, a director of Genpact Ltd. (G), was granted 6,521 restricted stock units (RSUs) on 2026-04-23. The award was recorded at $0.00 per unit (no cash paid) and thus has no immediate purchase cost or sale proceeds. Each RSU will convert into one common share when settled.

Key Details

• Transaction type: Award/Grant (Code A) of 6,521 RSUs on 2026-04-23, reported on Form 4 filed 2026-04-27 (filed within the SEC’s two-business-day window).
• Grant price: $0.00 per RSU (no cash exchanged at grant).
• Vesting/settlement: RSUs fully vest on December 31, 2026 (subject to continued service) and will be settled in common shares on December 31, 2027 (see footnote).
• Shares owned after transaction: Not specified in the filing.
• Footnote summary: Each RSU entitles the holder to receive one common share at settlement; the award is governed by the Genpact Limited 2017 Omnibus Incentive Compensation Plan.

Context

• This is a grant of deferred compensation (RSUs), not an open-market buy or sale. Grants are common for directors and employees as compensation and do not by themselves signal a buy or sell decision in the market. The RSUs will result in issuance of shares only after vesting and the stated settlement date.